Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 5/20 | 0.44 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | USP2 | O75604 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19375179 | 0.88 | ADORA1 (0.38) | TRPC5TRPC4KCNH2MAPTKMT2A | |
| SCHEMBL22619613 | 0.87 | TRPC5 (0.57) | TRPC5TRPC4KCNH2ALDH1A1TRPC1 | |
| SCHEMBL20432456 | 0.83 | TRPC5 (0.43) | TRPC5MAPTHTTLMNA | |
| SCHEMBL19375459 | 0.82 | TRPC5 (0.43) | TRPC5TRPC4KCNH2ALDH1A1MAPT | |
| SCHEMBL19505500 | 0.81 | TRPC5 (0.50) | TRPC5TRPC4KCNH2ALDH1A1KMT2A | |
| SCHEMBL19505249 | 0.81 | TRPC5 (0.49) | TRPC5TRPC4KCNH2ALDH1A1KMT2A | |
| SCHEMBL19374906 | 0.80 | TRPC5 (0.49) | TRPC5TRPC4KCNH2TRPC1ADORA3 | |
| SCHEMBL20432383 | 0.80 | — | — | |
| SCHEMBL19505572 | 0.79 | TRPC4 (0.47) | TRPC5TRPC4KCNH2TRPC1ADORA3 | |
| SCHEMBL18835341 | 0.79 | TRPC4 (0.41) | TRPC5TRPC4KCNH2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2970303-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885TRPC4 3/4885KCNH2 70/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885TRPC4 3/4885KCNH2 70/4885 |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885TRPC4 3/4885KCNH2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.